This clinical trial is focused on studying treatments for renal cell carcinoma, a type of kidney cancer. The study involves several medications, including MK-4280A (a combination of pembrolizumab and favezelimab), MK-1308A (a combination of pembrolizumab and quavonlimab), MK-7684A (a combination of pembrolizumab and vibostolimab), lenvatinib, and belzutifan. These treatments are being tested to see how safe and effective they are when used in combination.
The purpose of the study is to evaluate the safety and effectiveness of these treatment combinations. Participants will receive different combinations of the medications, which may be given as a solution for infusion (a liquid given through a vein) or as capsules or tablets taken by mouth. The study will monitor participants for any side effects and measure how well the cancer responds to the treatments.
The study is divided into two phases. The first phase focuses on assessing the safety and tolerability of the treatment combinations. The second phase evaluates the effectiveness of the treatments by looking at how the cancer responds. Participants will be closely monitored throughout the study to ensure their safety and to gather information on how well the treatments work against renal cell carcinoma.



France
Hungary
Poland
Spain
The Netherlands